COVID-19 in Patients With Chronic Liver Diseases
- Conditions
- Chronic Liver DiseaseCOVID-19
- Interventions
- Other: Prospective Chart Review
- Registration Number
- NCT04439084
- Lead Sponsor
- Stanford University
- Brief Summary
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1025
-
Confirmed diagnosis of COVID-19
-
Personal history of either
- Chronic hepatitis C
- Chronic hepatitis B
- Alcoholic liver disease
- Non alcoholic liver disease
- Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis
- Cryptogenic cirrhosis
- Hepatocellular carcinoma
- Non-COVID-19 patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Liver Disease Group Prospective Chart Review COVID-19 patients with Chronic Liver Disease. Control Group Prospective Chart Review COVID-19 patients without Chronic Liver Disease.
- Primary Outcome Measures
Name Time Method Liver-related mortality 1 year Death due to liver-related cause
All-cause mortality 1 year Death due to any cause
Overall survival Up to 1 year Patients will be assessed for this outcome for up to 1 year
Number of patients with hepatic decompensation Up to 1 year Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year
- Secondary Outcome Measures
Name Time Method Number of participants requiring mechanical ventilation Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Duration of hospitalization Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Length of intensive care unit (ICU) stay Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Number of patients requiring hospitalization Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Trial Locations
- Locations (23)
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University of Southern California
🇺🇸Los Angeles, California, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Mayo Clinic
🇺🇸Scottsdale, Arizona, United States
Georgetown University
🇺🇸Washington, District of Columbia, United States
VA Medical Center
🇺🇸Washington, District of Columbia, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
University of Miami
🇺🇸Miami, Florida, United States
Oschner Medical Center
🇺🇸Baton Rouge, Louisiana, United States
Hennepin County Medical Center (HCMC)
🇺🇸Minneapolis, Minnesota, United States
Duke University
🇺🇸Durham, North Carolina, United States
University of Arizona,
🇺🇸Phoenix, Arizona, United States
UCSF Fresno
🇺🇸Fresno, California, United States
Stanford University
🇺🇸Stanford, California, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
The University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States
Mount Sinai School of Medicine
🇺🇸New York, New York, United States
Weill Cornell Medicine
🇺🇸New York, New York, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States